Evidence map›Paper›PMID 33908816›Full record

ArticleHuman vaccines & immunotherapeutics2022

Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues.

Johnna Perdrizet, Carlos Felipe S Santana, Thais Senna, Rodrigo Fernandes Alexandre, Rodrigo Sini de Almeida, Julia Spinardi, Matt Wasserman

Open access · bronzeAbstract readLetter
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Johnna PerdrizetHealth Economics and Outcomes Research, Pfizer Inc, New York, NY, USA.ORCID 0000-0002-4260-7607
Carlos Felipe S SantanaHealth Economics and Outcomes Research, Pfizer Inc, Sao Paulo, Brazil.
Thais SennaHealth Economics and Outcomes Research, Pfizer Inc, Sao Paulo, Brazil.
Rodrigo Fernandes AlexandreHealth Economics and Outcomes Research, Pfizer Inc, Sao Paulo, Brazil.ORCID 0000-0002-1010-276X
Rodrigo Sini de AlmeidaMedical and Scientific Affairs, Pfizer Inc, Sao Paulo, Brazil.
Julia SpinardiMedical and Scientific Affairs, Pfizer Inc, Sao Paulo, Brazil.
Matt WassermanHealth Economics and Outcomes Research, Pfizer Inc, New York, NY, USA.ORCID 0000-0003-3300-2742
Pfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This communication seeks to address the questions and criticisms issued by Gomez and colleagues in their letter on our original study "Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants." Gomez and colleagues are concerned that the assumptions used in our model may have unintended negative impacts for Brazil decision-making and we intend to clarify any potential misinterpretation of our assessment.

Indexed as

Pneumococcal InfectionsBrazilCost-Benefit AnalysisHumansInfantPneumococcal VaccinesVaccines, ConjugatePneumococcal VaccinesVaccines, Conjugate

Identifiers

PMID33908816
PMCPMC8942431
OpenAlexW3158177696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.